Carvacrol, a monoterpenoid phenol primarily found in oregano oil, has gained attention for its antimicrobial and anti-inflammatory properties. The rationale for its use in acne management is largely based on laboratory studies demonstrating its ability to inhibit the growth of Cutibacterium acnes (formerly Propionibacterium acnes), the bacterium implicated in acne pathogenesis. Several in vitro studies have shown that carvacrol can disrupt bacterial cell membranes, leading to reduced bacterial viability. Additionally, carvacrol has been found to exert anti-inflammatory effects by suppressing the production of pro-inflammatory cytokines, which may help alleviate the inflammatory component of acne lesions.

However, clinical evidence supporting the use of carvacrol or carvacrol-containing products for acne in humans is limited. Most data come from preclinical models or cell culture studies, with very few small-scale clinical trials or case reports. There is a lack of robust, well-controlled human studies assessing its efficacy and safety as a topical or oral agent for acne treatment. Therefore, while there is a scientific basis for its potential benefit, the quality and quantity of clinical evidence are currently insufficient to strongly recommend its use. Larger, rigorous clinical trials are needed to confirm its effectiveness and safety profile in acne management.